rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-133-141rsp-2695Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESНовые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018)New guidelines for the management of patients with Behcet's disease/syndrome (EULAR, 2018)ЛисицынаТ. А.LisitsynaT. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115552

talisitsyna@rambler.ruАлекбероваЗ. С.AlekberovaZ. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115552

ГолоеваР. Г.GoloevaR. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115552

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201914052019572133141Copyright © Лисицына Т.А., Алекберова З.С., Голоева Р.Г., 20192019Лисицына Т.А., Алекберова З.С., Голоева Р.Г.Lisitsyna T.A., Alekberova Z.S., Goloeva R.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2695

Статья посвящена новым рекомендациям EULAR 2018 г. по ведению пациентов с болезнью/синдромом Бехчета (ББ), которые включают 5 принципов и 10 конкретных рекомендаций, касающихся лечения различных органных поражений. Рассмотрены методология их создания, а также нерешенные вопросы ведения пациентов с ББ, которые планируется исследовать в будущем.

The article is devoted to the new guidelines of EULAR on the management of patients with Behcet's disease/syndrome (BD), which include 5 principles and 10 specific recommendations for the treatment of various organ lesions. The methodology of their creation, as well as unresolved issues of management of patients with BD, which are planned to be investigated in the future, are considered.

болезнь БехчетарекомендацииBehcet's diseaserecommendationsReferencesHatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67:1656-62. doi: 10.1136/ard.2007.080432Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67:1656-62. doi: 10.1136/ard.2007.080432Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018 Jun;77(6):808-18. doi: 10.1136/annrheumdis-2018-213225Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018 Jun;77(6):808-18. doi: 10.1136/annrheumdis-2018-213225Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULARendorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULARendorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350Aktulga E, Altac M, Müftüoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica. 1980;65:399-402.Aktulga E, Altac M, Müftüoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica. 1980;65:399-402.Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum. 2001;44:2686-92. doi: 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-HYurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum. 2001;44:2686-92. doi: 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-HDavatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542-9. doi: 10.1007/s10165-009-0200-2Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542-9. doi: 10.1007/s10165-009-0200-2Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med Overseas Ed. 1990;322:281-5. doi: 10.1056/NEJM199002013220501Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med Overseas Ed. 1990;322:281-5. doi: 10.1056/NEJM199002013220501Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-50. doi: 10.7326/0003-4819-128-6-199803150-00004Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-50. doi: 10.7326/0003-4819-128-6-199803150-00004Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-71. doi: 10.1001/archderm.138.4.467Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-71. doi: 10.1001/archderm.138.4.467Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105.Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105.Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet's syndrome – a phase 2, placebo-controlled study. N Engl J Med Overseas Ed. 2015;372:1510-8. doi: 10.1056/NEJMoa1408684Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet's syndrome – a phase 2, placebo-controlled study. N Engl J Med Overseas Ed. 2015;372:1510-8. doi: 10.1056/NEJMoa1408684Tasli L, Mat C, De Simone C, et al. Lactobacilli lozenges in the management of oral ulcers of Behcet's syndrome. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S83-6.Tasli L, Mat C, De Simone C, et al. Lactobacilli lozenges in the management of oral ulcers of Behcet's syndrome. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S83-6.Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267-79. doi: 10.1111/j.1346-8138.2002.tb00263.xSharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267-79. doi: 10.1111/j.1346-8138.2002.tb00263.xMumcu G, Inanc N, Еzdemir FT, et al. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet's disease. Int J Dermatol. 2013;52:1561-6. doi: 10.1111/ijd.12144Mumcu G, Inanc N, Еzdemir FT, et al. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet's disease. Int J Dermatol. 2013;52:1561-6. doi: 10.1111/ijd.12144Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study.Arthritis Res Ther. 2017;19:69. doi: 10.1186/s13075-017-1222-3Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study.Arthritis Res Ther. 2017;19:69. doi: 10.1186/s13075-017-1222-3Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drugresistant Behcet's disease: a case series. Clin Rheumatol. 2015;34:1293-301. doi: 10.1007/s10067-013-2443-8Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drugresistant Behcet's disease: a case series. Clin Rheumatol. 2015;34:1293-301. doi: 10.1007/s10067-013-2443-8Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin Rheumatol. 2016;35:1281-6. doi: 10.1007/s10067-015-3004-0Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin Rheumatol. 2016;35:1281-6. doi: 10.1007/s10067-015-3004-0Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-87. doi: 10.1016/j.ophtha.2012.09.040Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-87. doi: 10.1016/j.ophtha.2012.09.040Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. Rheumatology. 2013;52:1923-4. doi: 10.1093/rheumatology/ket130Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. Rheumatology. 2013;52:1923-4. doi: 10.1093/rheumatology/ket130Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behcet's disease treated with tocilizumab. Clin Rheumatol. 2015;34:1141-3. doi: 10.1007/s10067-014-2589-zCantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behcet's disease treated with tocilizumab. Clin Rheumatol. 2015;34:1141-3. doi: 10.1007/s10067-014-2589-zMirouse A, Barete S, Monfort J-B, et al. Ustekinumab for Behcet's disease. J Autoimmun. 2017;82:41-6. doi: 10.1016/j.jaut.2017.05.002Mirouse A, Barete S, Monfort J-B, et al. Ustekinumab for Behcet's disease. J Autoimmun. 2017;82:41-6. doi: 10.1016/j.jaut.2017.05.002BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20(3 Suppl 4):136-43.BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20(3 Suppl 4):136-43.Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-3. doi: 10.1136/bjo.76.4.241Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-3. doi: 10.1136/bjo.76.4.241Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093-6. doi: 10.1016/S0140-6736(89)92381-7Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093-6. doi: 10.1016/S0140-6736(89)92381-7Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005;52:2478-84. doi: 10.1002/art.21231Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005;52:2478-84. doi: 10.1002/art.21231Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692-5. doi: 10.1007/s00417-006-0346-yTugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692-5. doi: 10.1007/s00417-006-0346-yBodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335-9. doi: 10.1136/bjo.2006.101550Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335-9. doi: 10.1136/bjo.2006.101550Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-4. doi: 10.1093/rheumatology/kem101Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-4. doi: 10.1093/rheumatology/kem101Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896-903.Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896-903.Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha-2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146:837-44. doi: 10.1016/j.ajo.2008.08.038Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha-2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146:837-44. doi: 10.1016/j.ajo.2008.08.038Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430-5. doi: 10.1016/j.ophtha.2009.11.022Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430-5. doi: 10.1016/j.ophtha.2009.11.022Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-γtreatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum. 2010;62:2796-805. doi: 10.1002/art.27581Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-γtreatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum. 2010;62:2796-805. doi: 10.1002/art.27581Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94:284-8. doi: 10.1136/bjo.2009.158840Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94:284-8. doi: 10.1136/bjo.2009.158840Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205-8. doi: 10.1136/bjo.2009.168856Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205-8. doi: 10.1136/bjo.2009.168856Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129:288-94. doi: 10.1001/archophthalmol.2011.3Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129:288-94. doi: 10.1001/archophthalmol.2011.3Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behcet's disease using infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S58-63.Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behcet's disease using infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S58-63.Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245-50. doi: 10.1136/bjo.2010.194464Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245-50. doi: 10.1136/bjo.2010.194464Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behcet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5-12. doi: 10.2147/BTT.S27343Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behcet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5-12. doi: 10.2147/BTT.S27343Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592-8. doi: 10.1001/archophthalmol.2011.2698Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592-8. doi: 10.1001/archophthalmol.2011.2698Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet's disease. Ocul Immunol Inflamm. 2012;20:198-202. doi: 10.3109/09273948.2012.670360Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet's disease. Ocul Immunol Inflamm. 2012;20:198-202. doi: 10.3109/09273948.2012.670360Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468-74. doi: 10.3109/09273948.2013.779727Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468-74. doi: 10.3109/09273948.2013.779727Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behcet's uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75-80. doi: 10.1007/s10384-013-0283-3Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behcet's uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75-80. doi: 10.1007/s10384-013-0283-3Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the longterm efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study. Ophthalmology. 2014;121:1877-84. doi: 10.1016/j.ophtha.2014.04.042Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the longterm efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study. Ophthalmology. 2014;121:1877-84. doi: 10.1016/j.ophtha.2014.04.042Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology. 2014;53:2223-31. doi: 10.1093/rheumatology/keu266Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology. 2014;53:2223-31. doi: 10.1093/rheumatology/keu266Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67-74. doi: 10.1016/j.jaut.2015.06.005Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67-74. doi: 10.1016/j.jaut.2015.06.005Jaffe GJ, Dick AD, Brеzin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med Overseas Ed. 2016;375:932-43. doi: 10.1056/NEJMoa1509852Jaffe GJ, Dick AD, Brеzin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med Overseas Ed. 2016;375:932-43. doi: 10.1056/NEJMoa1509852Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18:226-32. doi: 10.3109/09273948.2010.483314Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18:226-32. doi: 10.3109/09273948.2010.483314Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet's disease: experience in 19 patients. Rheumatology. 2012;51:1825-31. doi: 10.1093/rheumatology/kes130Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet's disease: experience in 19 patients. Rheumatology. 2012;51:1825-31. doi: 10.1093/rheumatology/kes130Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behcet's uveitis: a retrospective long-term followup study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58-62.Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behcet's uveitis: a retrospective long-term followup study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58-62.Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behcet's disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheum. 2017;69:2380-5. doi: 10.1002/art.40235Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behcet's disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheum. 2017;69:2380-5. doi: 10.1002/art.40235Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, doublemasked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183-92. doi: 10.1016/S0140-6736(16)31339-3Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, doublemasked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183-92. doi: 10.1016/S0140-6736(16)31339-3Grekas D, Nikolaidis P, Karamouzis M, et al. Effects of azathioprine on ciclosporin metabolism. Nephron. 1992;60:489. doi: 10.1159/000186816Grekas D, Nikolaidis P, Karamouzis M, et al. Effects of azathioprine on ciclosporin metabolism. Nephron. 1992;60:489. doi: 10.1159/000186816Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behcet's disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018;25:1-11. doi: 10.1080/09273948.2017.1421233Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behcet's disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018;25:1-11. doi: 10.1080/09273948.2017.1421233Ohguro N, Yamanaka E, Otori Y, et al. Repeated intravitreal triamcinolone injections in Behcet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218-20. doi: 10.1016/j.ajo.2005.08.013Ohguro N, Yamanaka E, Otori Y, et al. Repeated intravitreal triamcinolone injections in Behcet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218-20. doi: 10.1016/j.ajo.2005.08.013Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther. 2007;23:395-401. doi: 10.1089/jop.2007.0015Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther. 2007;23:395-401. doi: 10.1089/jop.2007.0015Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behcet disease. Ocul Immunol Inflamm. 2014;22:27-33. doi: 10.3109/09273948.2013.829109Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behcet disease. Ocul Immunol Inflamm. 2014;22:27-33. doi: 10.3109/09273948.2013.829109Seyahi E, Cakmak OS, Tutar B, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study. Medicine. 2015;94:e1899. doi: 10.1097/MD.0000000000001899Seyahi E, Cakmak OS, Tutar B, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study. Medicine. 2015;94:e1899. doi: 10.1097/MD.0000000000001899Tascilar K, Melikoglu M, Ugurlu S, et al. Vascular involvement in Behcet's syndrome: a retrospective analysis of associations and the time course. Rheumatology. 2014;53:2018-22. doi: 10.1093/rheumatology/keu233Tascilar K, Melikoglu M, Ugurlu S, et al. Vascular involvement in Behcet's syndrome: a retrospective analysis of associations and the time course. Rheumatology. 2014;53:2018-22. doi: 10.1093/rheumatology/keu233Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behcet’s syndrome: Effects of anti-TNF treatment. Semin Arthritis Rheum. 2015;45:369-73. doi: 10.1016/j.semarthrit.2015.06.008Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behcet’s syndrome: Effects of anti-TNF treatment. Semin Arthritis Rheum. 2015;45:369-73. doi: 10.1016/j.semarthrit.2015.06.008Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine 2012;91:35-48. doi: 10.1097/MD.0b013e318242ff37Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine 2012;91:35-48. doi: 10.1097/MD.0b013e318242ff37Le Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behcet's disease. A study in 25 patients. J Rheumatol. 1995;22:2103-13.Le Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behcet's disease. A study in 25 patients. J Rheumatol. 1995;22:2103-13.Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine. 2012;91:18-24. doi: 10.1097/MD.0b013e3182428126Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine. 2012;91:18-24. doi: 10.1097/MD.0b013e3182428126Park M-C, Hong B-K, Kwon HM, et al. Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease. Clin Rheumatol. 2007;26:1475-80. doi: 10.1007/s10067-006-0530-9Park M-C, Hong B-K, Kwon HM, et al. Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease. Clin Rheumatol. 2007;26:1475-80. doi: 10.1007/s10067-006-0530-9Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and longterm outcome of gastrointestinal involvement in Behcet's syndrome: a strobecompliant observational study from a dedicated multidisciplinary center. Medicine. 2016;95:e3348. doi: 10.1097/MD.0000000000003348Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and longterm outcome of gastrointestinal involvement in Behcet's syndrome: a strobecompliant observational study from a dedicated multidisciplinary center. Medicine. 2016;95:e3348. doi: 10.1097/MD.0000000000003348Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46:e38-e45. doi: 10.1097/MCG.0b013e3182431d56Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46:e38-e45. doi: 10.1097/MCG.0b013e3182431d56Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease.Inflamm Bowel Dis. 2012;18:750-7. doi: 10.1002/ibd.21757Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease.Inflamm Bowel Dis. 2012;18:750-7. doi: 10.1002/ibd.21757Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S129-37.Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S129-37.Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833-8. doi: 10.1097/MIB.0b013e31828f19c9Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833-8. doi: 10.1097/MIB.0b013e31828f19c9Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol. 2015;13:940-8. doi: 10.1016/j.cgh.2014.08.042Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol. 2015;13:940-8. doi: 10.1016/j.cgh.2014.08.042Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33-7. doi: 10.1007/s00296-009-1213-zGiardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33-7. doi: 10.1007/s00296-009-1213-zPipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285-90. doi: 10.1002/art.23345Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285-90. doi: 10.1002/art.23345Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-Behcet's disease: case series and literature review. Clin Rheumatol. 2011;30:1007-12. doi: 10.1007/s10067-011-1726-1Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-Behcet's disease: case series and literature review. Clin Rheumatol. 2011;30:1007-12. doi: 10.1007/s10067-011-1726-1Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3:e258. doi: 10.1212/NXI.0000000000000258Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3:e258. doi: 10.1212/NXI.0000000000000258Al-Araji ASA, Saip S. Treatment of NeuroBehcet's disease with infliximab: an international multi-centre case-series of 18 patients. Clin Exp Rheumatol. 2010;28(Suppl 60):S119.Al-Araji ASA, Saip S. Treatment of NeuroBehcet's disease with infliximab: an international multi-centre case-series of 18 patients. Clin Exp Rheumatol. 2010;28(Suppl 60):S119.Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum. 2015;44:472-5. doi: 10.1016/j.semarthrit.2014.08.004Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum. 2015;44:472-5. doi: 10.1016/j.semarthrit.2014.08.004Yazici H, Ugurlu S, Seyahi E. Behcet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43:275-80. doi: 10.1007/s12016-012-8319-xYazici H, Ugurlu S, Seyahi E. Behcet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43:275-80. doi: 10.1007/s12016-012-8319-x

The authors declare that there are no conflicts of interest present.